Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 273

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 273
---
 Total revenue12,500 — 17,500 — Operating expenses:Selling, general and administrative27,596 6,494 51,505 19,452 Research and development3,791 6,451 18,670 23,933 Total operating expenses31,387 12,945 70,175 43,385 Loss from operations(18,887)(12,945)(52,675)(43,385)Other income:Other (expense) income(14)(6)174 281 Interest income2,201 2,736 6,770 5,987 Total other income, net2,187 2,730 6,944 6,268 Net loss before income taxes(16,700)(10,215)(45,731)(37,117)Income tax expense— — 500 — Net loss$(16,700)$(10,215)$(46,231)$(37,117)Other comprehensive loss:Unrealized gain on marketable securities189 585 31 517 Comprehensive loss$(16,511)$(9,630)$(46,200)$(36,600)Net loss per share, basic and diluted$(0.59)$(0.38)$(1.65)$(1.93)Weighted-average common shares outstanding, basic and diluted (1)28,540,51927,172,33028,052,27919,195,399

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

(1)See Note 2 for further information on weighted-average common shares outstanding.

2

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY

(in thousands, except share data)

(unaudited)

Stockholders' EquityCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Stockholders' EquitySharesAmountBalance as of December 31, 202427,518,439$1 $348,901 $(145,014)$196 $204,084 Exercise of stock options11,630— 44 — — 44 Unrealized loss on marketable securities—— — — (73)(73)Vesting of early exercised stock options5,594—